The total output of finished pharmaceuticals in Q1–Q3 2025 amounted to RUB 716.1 billion (in manufacturer shipment prices, including VAT), representing a 15.7% increase year-on-year in value terms. According to the RNC Pharma® database “Pharmaceutical Production in Russia”, between January and September 2025, pharmaceutical manufacturers operating in Russia released more than 2.89 billion packages of finished medicinal products (FMPs) into circulation, equivalent to 61.1 billion minimal dosage units (MDUs). In physical terms, production volumes declined by 4.5% in packages, while in MDUs the decrease was marginal at –0.1%.

In September 2025, production volumes rose as expected: the total shipment value of finished pharmaceuticals reached RUB 84.9 billion, up 17% year-on-year. During the month, locally based manufacturers produced approximately 360.6 million packages, equivalent to 7.67 billion MDUs — an increase of 9.2% in packages and 13.4% in MDUs compared to September 2024.

Most key therapeutic groups showed solid, sustained growth in production. For example, the analgesics–antipyretics group grew by 7.4% in packages. The strongest growth rates among the top 20 groups were observed for lipid-lowering agents (3× year-on-year), topical antibacterials (2×), as well as diuretics (+79%) and platelet aggregation inhibitors (+78%). Output contraction was recorded mainly for nasal preparations and hypnotic/sedative agents.

More than 40% of domestic manufacturers recorded a decline in production volumes in unit terms over the first nine months of 2025. Among the top five producers, only Ozon Pharmaceuticals continued to show steady growth — shipment volumes rose by 31% in packages and 43% in MDUs versus Q1–Q3 2024. The company’s most dynamic products were Umifenovir (up 66×), followed by Enalapril (up 4×) and Bisoprolol (up 2×).

Pharmstandard dropped to second place, showing an almost 30% decline in production volumes, mainly due to reduced output of unbranded analgesics and antipyretics (such as citramon, paracetamol, and acetylsalicylic acid). Binnopharm ranked third, with a 12% decline, though the company reported strong growth in branded products such as Kagocel (up 2.5×) and Dexonal (up 10.6×).

Among the top 20 producers, notable results were also recorded by Zhenel RD (+52%), driven primarily by the production of formic alcohol, classified as an antirheumatic agent, and Pranafarm (+31.2%), where growth was mainly attributed to increased output of angiotensin II antagonists, particularly losartan.

Fig. Volume of finished pharmaceutical production in Russia (including output of foreign pharmaceutical companies at own and contract facilities), January 2024 – September 2025, in physical terms (packages) and value terms (rubles, in manufacturer prices including VAT)